PURPOSE: To determine the maximum tolerated dose of the combination of @entity3003 and Caelyx, a pegylated liposomal @entity632 , with promising activities in various solid @entity5 . @entity1 AND METHODS: Twenty-two @entity1 with various advanced solid @entity5 were included. Three dose levels of Caelyx were explored: 30, 35 and 40 mg/m2 in association with a fixed dose of @entity3003 (AUC 5) every 3 weeks. Dose escalation followed a modified continuous reassessment method. RESULTS: Dose-limiting @entity137 were almost exclusively hematological: 3 @entity1398 , 1 grade 4 @entity1398 lasting more than 7 days and 2 grade 4 @entity882 were observed. Grade 4 @entity1398 and @entity1398 were observed in 20 and 10% of courses, respectively. The median interval between courses was 25 days after cycle 1 and 27-28 days after subsequent cycles. @entity5515 , @entity33 and other non hematological @entity137 were mild and uncommon. One @entity1 experienced a severe anaphylactic reaction immediately after Caelyx infusion. No clinical @entity299 was observed. Three @entity1 responded to therapy including 2 clinical complete responses in relapsing @entity43 . CONCLUSION: The recommended dose for future studies is Caelyx 35 mg/m2 + @entity3003 AUC 5 every 3 or 4 weeks. Antitumor activity, especially in @entity43 , warrants further investigation in phase II studies.

Phase I study of pegylated liposomal @entity632 ( @entity632 ) in combination with XXXX in @entity1 with advanced solid @entity5 .

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart dysfunction'] @entity5515 :: ('MESH:D017499', 'Disease') :: ['Palmar-plantar erythrodysesthesia']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
